Press "Enter" to skip to content

New patent for Boehringer Ingelheim drug JARDIANCE

0
Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug JARDIANCE

Annual Drug Patent Expirations for JARDIANCE
Annual Drug Patent Expirations for JARDIANCE

Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are five patents protecting this drug and one Paragraph IV challenge.

JARDIANCE drug price trends.

Drug patent litigation for JARDIANCE.

This drug has one hundred and eigthy-seven patent family members in forty-three countries.

The generic ingredient in JARDIANCE is empagliflozin. Four suppliers are listed for this compound. Additional details are available on the empagliflozin profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug JARDIANCE
    Do NOT follow this link or you will be banned from the site!